IGC-AD1-Active + IGC-AD1-Placebo
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Trial Timeline
Oct 11, 2022 → Mar 30, 2026
NCT ID
NCT05543681About IGC-AD1-Active + IGC-AD1-Placebo
IGC-AD1-Active + IGC-AD1-Placebo is a phase 2 stage product being developed by IGC Pharma for Alzheimer Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05543681. Target conditions include Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer Disease were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05543681 | Phase 2 | Recruiting |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 21 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 32 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 47 |
| GSK4527226 | Alector | Phase 2 | 29 |
| AL002 + Placebo | Alector | Phase 2 | 25 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| donanemab | Eli Lilly | Phase 2 | 35 |
| ATH-1017 | LeonaBio | Phase 2/3 | 20 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 28 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 25 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 19 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 19 |